Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angiogenesis-dependent diseases containing pinosylvin or a pharmaceutically acceptable salt thereof as an active ingredient, a food composition for preventing or improving angiogenesis-dependent diseases containing pinosylvin or a pharmaceutically acceptable salt thereof as an active ingredient, a method for treating angiogenesis-dependent diseases including administering the pharmaceutical composition to a subject suspected of having the angiogenesis-dependent diseases, and a method for promoting angiogenesis including administering pinosylvin or a pharmaceutically acceptable salt thereof to a subject in need of angiogenesis promotion.

Abstract: A wireless power transmission apparatus for high efficiency energy charging, includes a resonator configured to transmit power, and a power supply unit configured to supply power to the resonator. The apparatus further includes a first switching unit configured to connect the resonator to the power supply unit, and disconnect the resonator from the power supply unit, and a controller configured to control the first switching unit based on an amount of current flowing into the resonator.

Abstract: Provided is an error amplifier. The error amplifier includes: an amplifying unit receiving first and second input signals and amplifying a voltage difference between the received first and second input signals; a first voltage generating unit generating first and second driving voltages for driving the amplifying unit; a second voltage generating unit generating first and second body voltages to implement a body biasing method; a cascode current source including first to fourth PMOS transistors to provide a bias current to the amplifying unit and the first voltage generating unit; and an output unit outputting a signal of the voltage difference amplified by the amplifying unit, wherein the first and third PMOS transistors receive the first body voltage through a body terminal and the second and fourth PMOS transistors receive the second body voltage through a body terminal.

Abstract: The present invention relates to a preparation method of implant comprising drug delivery layer and implant composition for living donor transplantation comprising the same, and more specifically, a preparation method of implant comprising drug delivery layer comprising preparing chitosan-bioactive glass composite solution; preparing drug-containing complex coating composition by adding drug in the chitosan-bioactive glass composite solution; and preparing drug delivery layer by electrophoresis of the complex coating composition on the surface of implant, and implant composition for living donor transplantation comprising the same. The implant composition according to the present invention is able to deliver the drug, and therefore to prevent inflammation, which may occur after the surgery, as well as to promote recovery depending on the type of drugs contained.

Abstract: A method for manufacturing a thin film transistor array panel according to an exemplary embodiment of the present invention includes, forming a gate electrode, a gate insulating layer, and an oxide semiconductor layer on a substrate, first heat treating the substrate comprising the oxide semiconductor layer, forming a source electrode and a drain electrode on the oxide semiconductor layer, the source and drain electrodes facing each other, and forming a passivation layer on the source electrode and the drain electrode. The first heat treating is performed at more than 1 atmosphere and at most 50 or less atmospheres.

Abstract: Provided is an error amplifier. The error amplifier includes: an amplifying unit receiving first and second input signals and amplifying a voltage difference between the received first and second input signals; a first voltage generating unit generating first and second driving voltages for driving the amplifying unit; a second voltage generating unit generating first and second body voltages to implement a body biasing method; a cascode current source including first to fourth PMOS transistors to provide a bias current to the amplifying unit and the first voltage generating unit; and an output unit outputting a signal of the voltage difference amplified by the amplifying unit, wherein the first and third PMOS transistors receive the first body voltage through a body terminal and the second and fourth PMOS transistors receive the second body voltage through a body terminal.

Abstract: A wireless power transmission apparatus includes a resonator configured to transmit power to another resonator, and a power supply unit configured to supply power to the resonator. The apparatus further includes a switching unit including a transistor configured to be turned on to connect the power supply unit to the resonator, and to be turned off to disconnect the power supply unit from the resonator, based on a control signal, and a diode connected in series to the transistor.

Abstract: A method and kit for measuring a concentration of an antibiotic are provided. The method of measuring a concentration of an antibiotic includes preparing magnetic particles bound to an antibiotic, preparing silica-coated fluorescent particles to which at least one antibody of the antibiotic is bound, allowing the magnetic particles to react with the silica-coated fluorescent particles, and irradiating the reacted silica-coated fluorescent particles with laser beams.

Abstract: The tinnitus testing apparatus of this invention comprises a control part that in turn comprises: an auditory stimulus generation part that can generate a stimulus; and an AEP acquisition and amplitude measurement part that can acquire auditory evoked potential (AEP) brain waves of a examinee due to said stimulus and measure the specific amplitude of said acquired brainwaves; wherein said auditory stimulus is one or more of: a 1st stimulus containing continuous noise and pulse noise; and a 2nd stimulus containing pulse noise and continuous noise with a silent gap.

Abstract: A through substrate structure, an electronic device package using the same, and methods for manufacturing the same are disclosed. First, a via hole pattern is formed by etching an upper surface of a first substrate. A pattern layer of a second substrate is formed on the first substrate by filling the via hole pattern with a material for the second substrate by reflow. A via hole pattern is formed in the pattern layer of the second substrate by patterning the upper surface of the first substrate. Moreover, a via plug filling the via hole pattern is formed by a plating process, for example, thereby forming a through substrate structure, which can be used in an electronic device package.

Abstract: The present invention relates to an aptazyme comprising an aptamer for hepatitis C virus (HCV) RNA-encoding component; a hammerhead ribozyme comprising an antisense sequence to microRNA at the site released by self-cleavage; and a communication module sequence that connects the aptamer and hammerhead ribozyme and triggers a self-cleavage activity of the hammerhead ribozyme upon binding of the aptamer with the HCV RNA-encoding component. The present aptazyme inhibits microRNA activity specifically in HCV proliferating cells and thus a composition of the present invention comprising the aptazyme can be effectively used for treatment of HCV-related diseases.

Abstract: A method for low-level laser irradiation for hearing loss reversal includes: generating low-frequency laser light; controlling an output intensity of the generated laser light; determining whether or not the wavelength and output of the laser light coincides with a preset reference wavelength and reference output intensity, respectively; and irradiating with the laser light into an inner ear through an external auditory meatus, wherein the reference wavelength is set in the range of 600 nm to 10,000 nm.

Abstract: The present invention relates to a highly efficient carbazole-based compound and to an organic electroluminescence device including the same. According to the present invention, provided are a compound for an organic electroluminescence device and an organic electroluminescence device including the compound, in which a carbazole-based phosphine oxide compound, which is a compound intended for an organic electroluminescence device, is employed to overcome the problems of conventional compounds for organic electroluminescence devices, i.e. those of instable thermal stability and low efficiency, and particularly, the compound of the present invention exhibits superior efficiency in pure-blue phosphorescent devices.

Abstract: The present invention relates to a method and an apparatus for lipid removal using infrared OPO laser. Specifically, the method and the apparatus can remove fat from a living body in a more energy-efficient, rapid and effective manner by irradiating fat in the living body directly with two infrared lasers having wavelengths of about 2,300 nm and about 1,980 nm, which are generated using a pump laser having a wavelength of about 1,064 nm as a light source.

Abstract: A through substrate structure, an electronic device package using the same, and methods for manufacturing the same are disclosed. First, a via hole pattern is formed by etching an upper surface of a first substrate. A pattern layer of a second substrate is formed on the first substrate by filling the via hole pattern with a material for the second substrate by reflow. A via hole pattern is formed in the pattern layer of the second substrate by patterning the upper surface of the first substrate. Moreover, a via plug filling the via hole pattern is formed by a plating process, for example, thereby forming a through substrate structure, which can be used in an electronic device package.

Abstract: The present invention relates to a carbazole-based phosphine oxide compound, and an organic electroluminescent device including the same. According to the present invention, provided are a compound for an organic electroluminescent device which can improve the thermal stability and efficiency characteristics which are unstable and low, respectively, corresponding to problems of known compounds for organic electroluminescent devices, and particularly, can implement excellent efficiency characteristics in a pure blue phosphorescent device, by using the carbazole-based phosphine oxide compound of the compound for the organic electroluminescent device, and the organic electroluminescent device. According to one aspect of the present invention, the carbazole-based phosphine oxide compound of the compound for the organic electroluminescent device is provided, and the organic electroluminescent device containing the same which can implement thermal stability and high efficiency characteristics is also provided.

Abstract: Disclosed herein are a recombinant adenovirus comprising tissue-specific promoters and trans-splicing ribozymes targeting tumor-specific genes, and uses thereof. More specifically, disclosed herein are a recombinant adenovirus comprising (1) a tissue-specific promoter, (2) a trans-splicing ribozyme acting on tumor-specific genes operably linked to the promoter, and (3) a therapeutic or reporter gene linked to 3? exon of the ribozyme, an anticancer pharmaceutical composition comprising the same, and a composition for cancer diagnosis comprising the same. The recombinant adenovirus exhibits high specificity and significantly improved therapeutic efficacy to gene targeted tissues. Accordingly, the recombinant adenovirus is useful as a gene delivery vector for anticancer agents or cancer diagnostics.

Abstract: The present invention relates to RNA aptamers and uses thereof, more precisely RNA aptamers interfering the interaction of TCF with other proteins by binding specifically to ?-catenin, RNA aptamers binding specifically to HMG domains of TCF-I proteins and uses of the same. The RNA aptamer of the present invention can be effectively used for the development of an anticancer agent since it binds specifically to TCF-I to interrupt the interaction of TCF with ?-catenin involved in tumorigenesis and metastasis and the transcriptional activity of TCF-I in relation to oncogenes.

Abstract: Provided is an allosteric trans-splicing group I ribozyme whose target-specific RNA replacement activity is controlled by theophylline, wherein the hTERT-targeting trans-splicing ribozyme recognizes mRNA of human telomerase reverse transcriptase (hTERT) as a cancer-specific RNA transcript to bind a theophylline aptamer to an hTERT target trans-splicing ribozyme via a communication module, the hTERT target trans-splicing ribozyme having a verified trans-splicing ability. The allosteric trans-splicing group I ribozyme may be useful to selectively diagnose only cancer cells that express target hTERT RNA, or induce their apoptosis since the activity of the allosteric trans-splicing group I ribozyme is dependently controlled by theophylline to correct target hTERT RNA by the trans-splicing reaction.